Bridging therapy considerations for CAR T therapy. BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; CD, clusters of differentiation; DCEP, dexamethasone, cyclophosphamide, etoposide, and cisplatin; PI, proteasome inhibitor; IMID, immunomodulatory drugs; VDPACE, bortezomib, dexamethasone, cisplatin, adriamycin, cyclophosphamide, and etoposide.